# Safety and Tolerability of I.V. Infusion of MB07133 in Patients With Unresectable Hepatocellular Carcinoma

> **NCT00073736** · PHASE1,PHASE2 · COMPLETED · sponsor: **Ligand Pharmaceuticals** · enrollment: 28 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** MB07133 300mg/m2/day
- **DRUG:** MB07133 600 mg/m2/day
- **DRUG:** MB07133 1200 mg/m2/day
- **DRUG:** MB07133 1800 mg/m2/day
- **DRUG:** MB07133 2400 mg/m2/day

## Key facts

- **NCT ID:** NCT00073736
- **Lead sponsor:** Ligand Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09
- **Primary completion:** 2007-07
- **Final completion:** —
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2011-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00073736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00073736, "Safety and Tolerability of I.V. Infusion of MB07133 in Patients With Unresectable Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00073736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*